Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S: PROSES study analysis by gender and age
Main Article Content
Keywords
Acne, PROSES, sarecycline, antibiotics, Real World Evidence, RWE
Abstract
Introduction: The objective of this analysis was to evaluate facial IGA and the associated IGA success, stratified by age and gender, among AV patients administered sarecycline in community practices across the U.S.
Methods: A single-arm, prospective cohort study (PROSES) was conducted with moderate-to-severe non-nodular AV patients >9 years who were prescribed sarecycline in real-world community practices in the US. Facial IGA of AV status was collected on a five-point adjectival response scale (0(clear)-4(severe)). IGA success at week-12 was defined as >2-grade improvement and score 0-clear or 1-almost clear at week-12. Proportion of patients achieving IGA success was analyzed, stratified by gender and age (9-17yrs, >=18yrs).
Results: A total of 253 AV patients completed the study (female: 66.40%; 9-17yrs: 39.92%; >=18yrs: 60.08%; Facial IGA success at week-12 was 56.47% for male and 60.12% for female; 57.43% for patients 9-17yrs old and 59.87% for patients >=18yrs old.
Conclusion: Within the study cohort of adolescent and adult patients with moderate to severe AV at baseline administered sarecycline, a narrow-spectrum, tetracycline-derived antibiotic for 12 weeks, across the gender and age groups, majority of patients achieved IGA success at week-12.
References
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.